What Egle Therapeutics does

Egle Therapeutics SAS is a privately held, clinical-stage biotechnology company founded in 2020 as a spin-off from Institut Curie and headquartered in Suresnes (Paris), France. The company develops a portfolio of antibody-based and engineered cytokine immunotherapies that selectively modulate regulatory T cells (Tregs) to either deplete them in solid tumors (oncology) or expand them in inflamed tissues (autoimmunity). Its lead oncology candidate, EGL-001, is an anti-CTLA-4 x IL-2 mutein fusion protein designed to induce tumor-selective Treg apoptosis via an Fc-receptor-independent mechanism with preferential tumor accumulation; EGL-002 is an anti-CCR8 x anti-CD25 bispecific fusion for enhanced tumor Treg depletion; and EGL-003 is an Fc-fused IL-2 mutein Treg engager in Phase 1 for atopic dermatitis. EGL-004, targeting an undisclosed tumor Treg antigen, sits in discovery.

The company operates two parallel portfolios — oncology (EGL-001/EGL-002/EGL-004) and autoimmunity (EGL-003) — with discovery enabled by a proprietary multi-omics and bioinformatics platform. To date Egle has initiated first-in-human Phase 1/2 trials for EGL-001 (NCT06622486, advanced/metastatic solid tumors, monotherapy and combination with anti-PD-(L)1) and Phase 1 for EGL-003 (healthy volunteers, expanding into atopic dermatitis), with top-line EGL-001 data expected H2 2026. The company collaborates with Takeda (strategic research partnership and investment via Takeda Ventures since 2020) and a Horizon Europe consortium of UCL, VHIO, Gustave Roussy, and TU Dresden for the EGL-001 neoadjuvant HNSCC program.

Egle has no commercial revenue and has not yet executed a material licensing or partnership transaction. Cumulative capital is approximately €56 million, comprising a €47 million Series A in October 2021 (EQT Life Sciences, Bpifrance, Fund Plus, Bioqube Factory Fund, T1D Fund, Takeda Ventures) plus approximately €17.3 million in non-dilutive public funding (€9.3M France 2030 in March 2025; €8M Horizon Europe in March 2026). The business model targets eventual pharma partnership for late-stage development and commercialization, complemented by direct commercialization optionality. Pricing is undisclosed pending regulatory approval. Leadership includes CEO John Celebi (appointed January 2026), Chairman Michel Detheux (former iTeos CEO), and a CXO team drawn from Roche/Genentech, Institut Curie, Effimune/Ose Immunotherapeutics, and Crescendo Biologics.

Name

Egle Therapeutics

Legal name

Egle Therapeutics SAS

Website

https://egle-tx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Egle Therapeutics is a clinical-stage French biotechnology company developing antibody and engineered IL-2 immunotherapies that selectively modulate regulatory T cells to treat solid tumors (EGL-001, EGL-002) and autoimmune diseases (EGL-003 for atopic dermatitis), founded in 2020 as a spin-off from Institut Curie and currently pre-revenue.

Ownership category

akta.pro rank

Product category

Immuno-oncology and autoimmune biologics (Treg-modulating immunotherapy pipeline)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Dermatology Specialty Pharmaceuticals (HLAIACAL), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• Treg immunotherapy
• Immuno-oncology biologics
• Regulatory T cell modulation
• Cancer immunotherapy pipeline
• Autoimmune disease biologics

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Development and Licensing: As a pre-commercial clinical-stage biotechnology company, Egle Therapeutics currently has no revenue. The company is developing novel Treg-focused immunotherapies and plans to commercialize through pharma partnerships or direct commercialization. The company has raised nearly €56 million through equity financing and non-dilutive public funding, including Series A financing and government grants.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Egle Therapeutics is a clinical-stage biotechnology company developing a pipeline of Treg-modulating immunotherapies for oncology and autoimmune diseases. Its lead oncology candidate EGL-001 is an anti-CTLA-4-IL-2m fusion protein in Phase 1/2 trials for solid tumors, its autoimmune lead EGL-003 is an IL-2 mutein Treg engager in Phase 1 for atopic dermatitis, supported by a proprietary multi-omics and bioinformatics Treg target discovery platform.

Product overview

Egle Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel Treg-focused immunotherapies for cancer and autoimmune diseases. The company operates two distinct portfolios: an oncology portfolio led by EGL-001 (anti-CTLA-4-IL-2m fusion) and EGL-002 (anti-CCR8 x anti-CD25 bispecific), and an autoimmunity portfolio led by EGL-003 (IL-2 Treg engager). EGL-004 represents an additional undisclosed tumor Treg target in earlier development. The company's proprietary technology platform combines multi-omics analyses with computational IL-2 design to develop selective antibody-based candidates that either inhibit Tregs in tumors or expand Tregs in inflamed tissues.

Differentiator

Problem solved

Functional benefit

Products and services

• EGL-001 EGL-001 is an anti-CTLA-4 x IL-2m fusion protein (immunocytokine Treg starver) designed to selectively disarm and remove regulatory T cells in the tumor microenvironment while blocking CTLA-4 to restore effector T-cell priming and function. It induces tumor-selective Treg apoptosis through an Fc receptor-independent mechanism, with preferential tumor accumulation and rapid clearance from peripheral organs. It is currently in Phase 1/2 clinical trials for solid tumors, including HNSCC in combination with pembrolizumab.
• EGL-002 EGL-002 is a novel anti-CCR8 x anti-CD25 bispecific fusion antibody engineered to achieve prolonged retention on the surface of tumor-infiltrating Tregs, avoiding rapid internalization that limited efficacy of conventional CCR8 antibodies. It delivers superior ADCC and ADCP potency resulting in near-complete tumor Treg depletion, intended for solid tumor indications.
• EGL-003 EGL-003 is a next-generation Fc-fused IL-2 mutein (Treg engager) engineered for potent, selective activation of regulatory T cells while sparing conventional effector T cells. It maintains IL-2-like full agonism on Tregs and features a pharmacokinetic profile designed to deliver intermittent, physiological bursts of signaling for selective expansion of tissue-resident Tregs in autoimmune indications such as atopic dermatitis.
• EGL-004 EGL-004 is a novel monoclonal antibody targeting undisclosed tumor Treg targets for cancer treatment, currently in the discovery/preclinical stage of development.

Quantifiable outcome

• EGL-001 showed preferential tumor accumulation and persistence while rapidly clearing from healthy tissues in biodistribution studies
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core.

• University College London (UCL)coreStrategic or Co-development Partner · 2 March 2026European research institution partner in the Horizon Europe €8 million grant consortium. UCL will collaborate on the multicenter Phase 1/2 clinical trial evaluating EGL-001 in neoadjuvant HNSCC and contribute to translational research program including multi-omics profiling and AI-driven pathomics modeling.
• Vall d'Hebron Institute of Oncology (VHIO)coreStrategic or Co-development Partner · 2 March 2026European research institution partner in the Horizon Europe €8 million grant consortium. VHIO will participate in the multicenter clinical trial and translational research program for EGL-001 in head and neck squamous cell carcinoma.
• Gustave RoussycoreStrategic or Co-development Partner · 2 March 2026Leading European cancer research center partner in the Horizon Europe €8 million grant consortium. Prof. Aurélien Marabelle from Gustave Roussy is quoted supporting the EGL-001 approach. Gustave Roussy contributes clinical trial capacity and expertise in immunology and immuno-oncology.
• Technical University of DresdencoreStrategic or Co-development Partner · 2 March 2026European research institution partner in the Horizon Europe €8 million grant consortium. TU Dresden will contribute to the clinical trial and translational research program for EGL-001, providing expertise in computational biology and genomics.
• Takeda PharmaceuticalscoreStrategic or Co-development Partner · 1 June 2020Strategic partnership established in June 2020 as a three-year research collaboration with an option agreement. Since its inception, the company has partnered with Takeda for research and development in Treg-focused therapies. Takeda Ventures holds an investment position and board representation through Mojgan Hossein-Nia as board member representative.
• Institut CuriecoreStrategic or Co-development Partner · 1 January 2020Egle Therapeutics was founded in 2020 as a spin-off from Institut Curie, a leading French cancer research institution. The company leverages research expertise and intellectual property developed at Institut Curie in the field of regulatory T cells and cancer immunology.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• iTeos Therapeutics: Clinical-stage immuno-oncology company developing Treg- and TIGIT-targeting antibodies. Closest direct peer — Egle's chairman Michel Detheux was iTeos' founding CEO and led the $2B+ TIGIT collaboration with GSK, illustrating the strategic adjacency.
• OSE Immunotherapeutics: French clinical-stage immunology company developing IL-7 (OSE-127) and Tedopi for oncology and autoimmune indications. Closely comparable as a European Treg/immunomodulation biotech; Egle's CDO Bernard Vanhove was previously COO at OSE.
• Werewolf Therapeutics: Clinical-stage biotech engineering INDUKINE molecules (masked cytokines, including IL-2 variants) for selective tumor immune activation. Directly comparable to Egle's IL-2 mutein and fusion-cytokine approach in oncology.
• Xilio Therapeutics: Clinical-stage biotech developing tumor-selective immunotherapies including masked IL-2 (XTX101) and IL-12. Directly comparable platform thesis: tissue-restricted cytokine activation analogous to Egle's Treg-selective IL-2 design.
• Crescendo Biologics: Clinical-stage UK biotech developing T cell engager biologics (CD20 x CD3, etc.). Directly comparable as a European antibody-engineering platform biotech; Egle's CMO Kenji Hashimoto was previously CMO at Crescendo.
• Sensei Bio: Clinical-stage immuno-oncology biotech developing bacteriophage-based cancer vaccines and TNFR2-targeting antibodies. Highly comparable as a small-molecule-meets-immuno-oncology platform where Egle's CEO John Celebi was previously CEO and led the company to a $152M IPO.

Broad incumbents

• AnaptysBio: Clinical-stage antibody-focused biotech with pipeline including IL-36R (pegozumaftab) and PD-1 agonist (rosnilimab) for autoimmune disease. Overlaps with Egle on antibody engineering for immunology indications and is a likely BD counterparty.

Emerging players

• Effimune: French early-stage biotech developing immunomodulatory antibodies for autoimmunity and transplantation, founded by Egle CDO Bernard Vanhove. Direct comparable in mechanism (Treg modulation) and origin ecosystem.
• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) to target tumors via innate and adaptive immunity. Comparable as a small-molecule-engineered antibody platform pursuing tumor-selective immune activation in solid tumors.
• Cullinan Oncology: Clinical-stage oncology biotech with multiple programs across immuno-oncology modalities. Comparable as a hub-and-spoke clinical-stage biotech pursuing differentiated mechanisms in oncology through partnerships and internal programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/egle-tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egle Therapeutics